Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. Hutchison RM, Fraser K, Yang M, Fox T, et al. Neurology 2024;102:e209137.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hutchison RM, Fraser K, Yang M, Fox T, et al. Cinpanemab in Early Parkinson Disease: Evaluation of Biomarker Results From the Phase 2 SPARK Clinical Trial. Neurology 2024;102:e209137.
PMID: 38315945